

PRIOR AUTHORIZATION REQUEST

Emflaza

Patient Information:			
Name:			
Member ID:			
Address:			
City, State, Zip:			
Date of Birth:			
Prescriber Information:			1
Name:			
NPI:			
Phone Number:			
Fax Number			
Address:			
City, State, Zip:			
Requested Medication			
Rx Name:			
Rx Strength			
Rx Quantity:			
Rx Frequency:			
Rx Route of			
Administration:			
Diagnosis and ICD Code:			
prescribed a medication for you quantities can be provided. Ple Upon receipt of the complete SECTION A: Please no requests. Pharmacy predications that are not prescribed as the control of the control of the complete predications that are not predications that are not predications that are not predicated as the control of the control o	efit requires that we review certain requests for coverage with the purpatient that requires Prior Authorization before benefit coverage or consider the following questions then fax this form to the toll-free read form, prescription benefit coverage will be determined based on the that supporting clinical documentation is required in the criterial documentation is required in the criteria. The policies are subject to the this, MDH transmittals and updates to treatment quickless.	overage of number lise on the pland d for AL addition o chance	additional ted below. an's rules. LPA nal ge based
1 Is the patient curre [If no, skip to ques	ently receiving Emflaza/Deflazacort? tion 4]	Yes	No
2 Has the patient be [If yes, skip to que	en receiving medication samples for the requested medication? stion 4]	Yes	No
significant respons	n been submitted to confirm that the patient has had a clinically se to therapy, as determined by the provider? ACTION nit supporting documentation.	Yes	No

If you have any questions, call: 1-888-258-8250

Version 07.2025

PRIOR AUTHORIZATION REQUEST

	TALL Configurations 1		
	[No further questions.]		
4	What is the diagnosis or indication? [] Duchenne Muscular Dystrophy (DMD) (If checked, go to 5)		
	[] Other (If checked, no further questions)		
5	What is the requested medication?		
	[] Deflazacort (generic) (If checked, go to 7)		
	[] Emflaza (brand) (If checked, go to 6)		
6	Has the patient had a trial and failure of the generic product, deflazacort? [If no, no further questions]	Yes	No
7	Is the patient greater than or equal to 2 years of age? [If no, no further questions.]	Yes	No
8	Is the requested medication being prescribed by or in consultation with a physician who specializes in the treatment of Duchenne Muscular Dystrophy (DMD) and/or neuromuscular disorders? [If no, no further questions.]	Yes	No
9	Is documentation being provided to confirm that the patient has tried prednisone for GREATER THAN or EQUAL to 6 months? ACTION REQUIRED: Submit supporting documentation. [If yes, no further questions.]	Yes	No
10	Is documentation being provided to confirm that, according to the prescriber, the patient has had a significant intolerable adverse effect (that is Cushingoid appearance, central [truncal] obesity, undesirable weight gain defined as a GREATER THAN or EQUAL TO 10% of body weight gain increase over a 6-month period, diabetes and/or hypertension that is difficult to manage according to the prescriber)? ACTION REQUIRED: Submit supporting documentation. [If yes, no further questions.]	Yes	No
11	Is documentation being provided to confirm that, according to the prescriber, the patient has experienced a severe behavioral adverse effect while on prednisone therapy that has or would require a prednisone dose reduction? ACTION REQUIRED: Submit supporting documentation.	Yes	No

Please document the diagnoses, symptoms, and/or any other information important to this review:



PRIOR AUTHORIZATION REQUEST

SECTION B: Physician Signature

PHYSICIAN SIGNATURE

DATE

FAX COMPLETED FORM TO: 1-833-896-0656

Disclaimer: An authorization is not a guarantee of payment. Member must be eligible at the time services are rendered. Services must be a covered Health Plan Benefit and medically necessary with prior authorization as per Plan policy and procedures.

Confidentiality: The information contained in this transmission is confidential and may be protected under the Health Insurance Portability and Accountability Act of 1996. If you are not the intended recipient any use, distribution, or copying is strictly prohibited. If you have received this facsimile in error, please notify us immediately and destroy this document.